Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

8 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MRNA expression data of tumor samples with/without IDH1/2 mutations and of controls

ABSTRACT: We determined differentially expressed genes between tumor samples with and without IDH1/2 mutations, and between tumors with IDH1/2 mutations and controls. A total of 21 tumours which include 6 enchondromas and 10 chondrosarcomas (3 grade I, 7 grade II) of Ollier disease, as well as 1 enchondroma and 4 chondrosarcomas grade II of solitary tumors, and 6 controls (growth plate and cartilage) were selected for expression analysis. Sample preparation, RNA isolation, synthesis of cDNA, cRNA amplification, hybridization of cRNA onto the Illumina Human-6 v3.0 Expression BeadChips, microarray data preprocessing, quality control, and detection of differential expression were performed as described previously (PMID: 21372215, PMID: 21584901). We determined differential expression between tumor samples without detectable IDH1 or IDH2 mutation (n=3) and samples with IDH1 or IDH2 mutations (n=18), and between samples with IDH1 or IDH2 mutation and controls (n=6). Probes with Benjamini and Hochberg False discovery rate-adjusted P-values (adjP) < 0.05 and a log fold change (logFC) > 0.1 were considered to be significantly differentially expressed.

ORGANISM(S): Homo sapiens

SUBMITTER: Twinkal Pansuriya

PROVIDER: E-GEOD-30835 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Expression array using Maffucci tumours

Project description:We did whole genome analysis of enchondromas and chondrosarcomas of Maffucci patients. Since the disease is very rare, we had only three frozen tumour samples were available to continue with the expression array. Enchondromas of Maffucci syndrome did not show any loss of heterozygosity (LOH) or common copy number alterations (CNA) and we looked at the differentially expressed genes between Ollier high grade and Maffucci high grade tumours. There were no significant differentially expressed genes were found between these two groups. This might be due to the small sample size. We used Affymetrix SNP 6.0 array on enchondromas (n=4) and chondrosarcomas (n=2) and compared the results to a previously studied cohort of patients with Ollier disease (n = 37). We used Illumina expression array v3 chip on enchondroma (n=1) and chondrosarcomas (n=2) from Maffucci patients.

2011-07-18 | E-GEOD-26667 | biostudies-arrayexpress

Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell haemangioma in Ollier disease and Maffucci syndrome

Project description:This SuperSeries is composed of the following subset Series: GSE30354: Examination of Ollier Disease and Maffucci Syndrome using IDH Tiling Array GSE30835: mRNA expression data of tumor samples with/without IDH1/2 mutations GSE31337: Methylation profiling of enchondromas with and without IDH1 mutations Refer to individual Series

2011-11-05 | E-GEOD-30844 | biostudies-arrayexpress

Examination of Ollier Disease and Maffucci Syndrome using IDH Tiling Array

Project description:Ollier disease and Maffucci syndrome are non-hereditary skeletal disorders characterized by multiple enchondromas (Ollier) combined with spindle cell hemangiomas (Maffucci). We found somatic heterozygous IDH1 mutations (R132C and R132H) in 83% of enchondromas, benign cartilage tumors, as well as in 40% of spindle cell hemangiomas, benign vascular lesions. In total, 33 of 42 (78%) patients with Ollier disease and 7 of 13 (54%) patients with Maffucci syndrome carried a mutation in at least one of their tumors. Twelve patients with multiple tumors at different locations displayed identical mutations in separate lesions. Immunohistochemical staining for the R132H IDH1 mutant protein suggested intraneoplastic as well as somatic mosaicism. IDH1 mutations were less frequent (63%) in high grade malignant cartilage tumors in Ollier disease, suggesting that IDH1 is less important for malignant transformation. IDH1 and IDH2 mutations were found in 36% of sporadic cartilage tumors and in four cell lines derived from sporadic chondrosarcomas. 16 samples were analyzed in two color experiment, using normal male or female as a reference sample (gender mismatched)

2011-11-05 | E-GEOD-30354 | biostudies-arrayexpress

Induction of sarcomas by mutant IDH2

Project description:More than 50% of patients with chondrosarcomas exhibit gain-of-function mutations in either isocitrate dehydrogenase 1 (IDH1) or IDH2. In this study, we performed genome-wide CpG methylation sequencing of chondrosarcoma biopsies and found that IDH mutations were associated with DNA hypermethylation at CpG islands but not other genomic regions. Regions of CpG island hypermethylation were enriched for genes implicated in stem cell maintenance/differentiation and lineage specification. In murine 10T1/2 mesenchymal 20 progenitor cells, expression of mutant IDH2 led to DNA hypermethylation and an impairment in differentiation that could be reversed by treatment with DNA-hypomethylating agents. Introduction of mutant IDH2 also induced loss of contact inhibition and generated undifferentiated sarcomas in vivo. The oncogenic potential of mutant IDH2 correlated with the ability to produce 2-hydroxyglutarate. Together, these data demonstrate that neomorphic IDH2 mutations can be oncogenic in mesenchymal cells.. RRBS sequencing of (1) IDH wild type and mutant human chondrosarcomas, (2) isogenic cell lines expressing wild-type or mutant IDH.

2013-10-21 | E-GEOD-50539 | biostudies-arrayexpress

Examination of Ollier Disease and Maffucci Syndrome using IDH Tiling Array

2011-11-05 | GSE30354 | GEO

Patient glioma microarray for Impaired histone demethylation contributes to the cell differentiation arrest induced by cancer-associated isocitrate dehydrogenase mutation

Project description:To study the effects of IDH mutations, we collected and performed gene expression microarray analysis with tumor specimens from patients with grade II-III oligodendroglioma. Sequencing for mutations of IDH1 and IDH2 was done. Gene expression was compared between IDH wildtype vs. mutant samples

2012-02-01 | E-MEXP-3239 | biostudies-arrayexpress

Induction of sarcomas by mutant IDH2

2013-10-21 | GSE50539 | GEO

Mutations in IDH1 and IDH2 are associated with DNA hypermethylation in intrahepatic cholangiocarcinomas

Project description:We compared the DNA methylation profiles of 12 intrahepatic cholangiocarcinomas harboring mutations in the genes encoding isocitrate dehydrogenase, IDH1 and IDH2, with 28 intrahepatic cholangiocarcinomas without these mutations. We profiled these samples with the Illumina HumanMethylation450 BeadChip, and characterized over 2,000 genes that were hypermethylated in tumors with mutations in IDH1 or IDH2.

2012-06-11 | GSE32079 | GEO

Mutations in IDH1 and IDH2 are associated with DNA hypermethylation in intrahepatic cholangiocarcinomas

2012-06-10 | E-GEOD-32079 | biostudies-arrayexpress

DNA hypermethylation in intrahepatic cholangiocarcinomas and glioblastomas

Project description:This SuperSeries is composed of the following subset Series: GSE32079: Mutations in IDH1 and IDH2 are associated with DNA hypermethylation in intrahepatic cholangiocarcinomas GSE32283: Mutations in IDH1 are associated with DNA hypermethylation in glioblastomas Refer to individual Series

2012-06-09 | E-GEOD-32286 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data